

Liver Total Approach


@asyDetection



@Scan



@asyMode



@asyColor



Follow Up &
Multimodality



Extended
Field of View

@asyCharacterization



microV



ADM



CnTI™



QPack

@asyStaging



QElaXto 2D



QAI



Virtual
Navigator

@asyProcedures



Virtual Biopsy



MyLabRemote2.0

Esaote solutions
from detection to therapy
**Easy and complete
ultrasound liver
assessment**

N E V E R S T O P S E E I N G T H E U N S E E N .


esaote

Esaote **Liver Total Approach** solution: a complete horizon in liver ultrasound imaging




Single Crystal technology

Associated with the new generation of signal post-processing, Single Crystal technology enables extended bandwidth, for homogeneous images even in deep areas. Alongside conventional convex probes, Esaote also offers a 0° biopsy probe to facilitate interventional procedures.




Liver vascularization

microV is a brand-new Doppler technology with an astonishing degree of sensitivity in very small vessels, for slow flow detection.



Fibrosis Assessment

QelaXto 2D uses US elastosonography as an additive imaging technique, providing a stiffness map and quantitative assessment.




Steatosis Assessment

QAI enables the visualization and quantification of the attenuation along the liver depth, to assess hepatic steatosis.




Lesion characterization with CEUS

CnTI™ enables detection of organ perfusion and characterises liver lesions at high sensitivity. QPack provides quantitative information about the contrast medium perfusion.



Biopsy and treatment procedure

Virtual Navigator provides active coupling of real-time US and second-modality (MRI, CT) as a reference and enables needle tracking capability.



Virtual Biopsy

Esaote **Virtual Biopsy** technology enables the virtual path of the needle to find the best approach and insertion point to reach the target.



0123

Esaote S.p.A. - sole-shareholder company - Via Enrico Meloni 77, 16152 Genova, ITALY, Tel. +39 010 6547 1, Fax +39 010 6547 275, info@esaote.com

MyLab is a trademark of Esaote spa. CnTI™: The use of Contrast Agents in the USA is limited by FDA to left ventricle opacification and to characterization of focal liver lesions. Technology and features are system/configuration dependent. Specifications subject to change without notice. Information might refer to products or modalities not yet approved in all countries. Product images are for illustrative purposes only. For further details, please contact your Esaote sales representative.

N E V E R S T O P S E E I N G T H E U N S E E N .

